Scientific studies have verified that cancer is caused by the genetic mutation of human body; genetic mutation can lead to infinite proliferation of cells due to losing of normal control ability, eventually resulting in occurrence of cancer. While the targeted drugs can kill the tumor cells carrying specific gene variations, with apparent curative effects, therefore, it is regarded as a first choice for advanced cancer patients in multiple cancer types. Presently, Imatinib, Sunitinib, Regorafenib and so on have been approved by FDA/CFDA. But, the gene variations carried by different patients are different, which makes patients with different sensitivity, toxic and adverse effects for same antineoplastic drugs.
The precision diagnosis is a prerequisite for accurate medication. The idea of molecular genotype makes the doctors formulate best therapeutic regimen according to biomarkers carried by GIST patients and corresponding clinical status, to greatly find out potentially available targeted drugs and enhance treatment efficiency of antineoplastic drugs.
The occurrence of tumors is often accompanied by multiple gene variations and heterogeneity. The second generation sequencing technology can realize parallel detection on multiple genes, saving samples compared to traditional detection methods and reaching higher technology sensitivity, to restore tumor mutation in a more real manner.